ERCC4 (DNA repair endonuclease XPF) variants and mutations
ERCC4 (also known as DNA repair endonuclease XPF) is a human protein-coding gene encoding a DNA repair endonuclease XPF protein. Together with ERCC1, it makes structure-specific DNA incisions required for nucleotide-excision repair and interstrand-crosslink repair. Biallelic pathogenic variants can cause xeroderma pigmentosum, Fanconi anemia, or severe progeroid DNA-repair disease. This analysis covers 1,851 ERCC4 variants and mutations. Of these, 68% have computational variant effect predictions. Disease context includes xeroderma pigmentosum group F, Fanconi anemia complementation group Q, and xeroderma pigmentosum. Example ERCC4 variants include M1?, M1R, and M1T.
Variant analysis overview
- Gene: ERCC4
- Protein: DNA repair endonuclease XPF
- UniProt accession: Q92889
- Organism: Homo sapiens
- Variants analyzed: 1851
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,611 unspecified-consequence records; 8 stop-gained variants; 125 missense variants; 85 synonymous variants; 10 frameshift variants; 4 in-frame deletions; 2 splice-region variants; 1 splice acceptor variant; 5 substitution
- Prediction scores: 1,267 variants have prediction scores (68% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: xeroderma pigmentosum group F, Fanconi anemia complementation group Q, xeroderma pigmentosum, Xeroderma pigmentosum complementation group F, xeroderma pigmentosum-Cockayne syndrome complex, XFE progeroid syndrome, Fanconi anemia, Cockayne syndrome, xeroderma pigmentosum, type F/Cockayne syndrome, acute myeloid leukemia, myelodysplastic syndrome, isolated growth hormone deficiency type IA.
Protein structure and variant hotspots
- Protein features: 1 domains; 4 post-translational modification sites.
- Structural context: 170 variants have structural context.
- PTM context: 6 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable ERCC4 variants
Examples include M1?, M1R, M1T, M1V, E2A, E2K, E2Q, E2*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV6131, cosmic curated COSV61314, Variant assessed as somatic; high impact.
- M1R (p.Met1Arg), rs778859873, ClinGen CA7910052, ClinVar RCV002957387, MetaLR 0.15, MetaSVM -0.83, Uncertain significance, Fanconi anemia complementation group Q; Xeroderma pigmentosum, group F; Cockayne
- M1T (p.Met1Thr), rs778859873, ClinGen CA394815723, ClinVar RCV001774849, MetaLR 0.15, MetaSVM -0.83, Uncertain significance, not provided
- M1V (p.Met1Val), rs543978998, ClinGen CA394815713, ClinVar RCV003154575, MetaLR 0.10, MetaSVM -0.93, Uncertain significance, Fanconi anemia complementation group Q
- E2A (p.Glu2Ala), TOPMed rs2031937419, REVEL 0.09, CADD 23.30
- E2K (p.Glu2Lys), rs373789508, cosmic curated COSV61312, ESP rs373789508, TOPMed rs373789508, REVEL 0.10, AlphaMissense 0.14, Uncertain significance
- E2Q (p.Glu2Gln), rs373789508, ClinGen CA394815748, ClinVar RCV001219171, ESP rs373789508, AlphaMissense 0.14, MetaLR 0.12, Uncertain significance, Fanconi anemia complementation group Q; Xeroderma pigmentosum, group F; Cockayne
- E2* (p.Glu2Ter), gnomAD 16-13920169-G-T, CADD 39.00
- E2D (p.Glu2Asp), gnomAD 16-13920171-G-T, REVEL 0.07, CADD 22.60
- E2E (p.Glu2Glu), rs749985757, gnomAD 16-13920171-G-A, CADD 9.37
- S3* (p.Ser3Ter), ESP rs148904556, ExAC rs148904556, TOPMed rs148904556, gnomAD rs148904556, Uncertain significance
- S3A (p.Ser3Ala), TOPMed rs1295286028, gnomAD rs1295286028, REVEL 0.05, CADD 9.71
- S3L (p.Ser3Leu), rs148904556, ClinGen CA7910055, ClinVar RCV000362531, ClinVar RCV003765689, REVEL 0.32, CADD 13.90, Uncertain significance, Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementatio
- S3T (p.Ser3Thr), gnomAD 16-13920172-T-A, REVEL 0.04, CADD 8.76
- S3P (p.Ser3Pro), gnomAD 16-13920172-T-C, REVEL 0.05, CADD 7.32
- S3S (p.Ser3Ser), gnomAD 16-13920174-A-T, CADD 7.59
- G4R (p.Gly4Arg), ExAC rs768243270, gnomAD rs768243270, REVEL 0.09, CADD 16.30
- G4A (p.Gly4Ala), gnomAD 16-13920175-G-GCC, CADD 22.90
- G4W (p.Gly4Trp), gnomAD 16-13920175-G-T, REVEL 0.14, CADD 23.10
- G4V (p.Gly4Val), gnomAD 16-13920176-G-T, REVEL 0.05, CADD 14.30
- G4G (p.Gly4Gly), rs781417413, gnomAD 16-13920177-G-C, CADD 0.77
- Q5* (p.Gln5Ter), Ensembl rs2141936859, CADD 31.00
- Q5L (p.Gln5Leu), Ensembl rs2141936863
- Q5S (p.Gln5Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q5P (p.Gln5Pro), gnomAD 16-13920179-A-C, REVEL 0.05, CADD 0.25
- Q5Q (p.Gln5Gln), rs748509102, gnomAD 16-13920180-G-A, CADD 4.59
- Q5H (p.Gln5His), gnomAD 16-13920180-G-T, REVEL 0.07, CADD 6.96
- P6A (p.Pro6Ala), 1000Genomes rs61760160, ESP rs61760160, ExAC rs61760160, TOPMed rs61760160, REVEL 0.04, CADD 7.21, Uncertain significance
- P6L (p.Pro6Leu), rs2031938186, ClinGen CA394815834, ClinVar RCV001294107, TOPMed rs2031938186, REVEL 0.03, CADD 19.30, Uncertain significance, Fanconi anemia complementation group Q
- P6R (p.Pro6Arg), TOPMed rs2031938186, Uncertain significance
- P6S (p.Pro6Ser), rs61760160, ClinGen CA158855, ClinVar RCV000120803, ClinVar RCV000475143, REVEL 0.30, CADD 8.19, Uncertain significance, Cockayne syndrome; Xeroderma pigmentosum, group F; Fanconi anemia complementatio
- P6T (p.Pro6Thr), gnomAD 16-13920181-C-A, REVEL 0.04, CADD 8.78
- P6Q (p.Pro6Gln), gnomAD 16-13920182-C-A, REVEL 0.01, CADD 18.80
- P6P (p.Pro6Pro), gnomAD 16-13920183-G-T, CADD 11.10
- A7G (p.Ala7Gly), TOPMed rs1319883296, Uncertain significance
- A7T (p.Ala7Thr), rs771117594, ClinGen CA7910062, ClinVar RCV000688763, ClinVar RCV004972857, REVEL 0.11, CADD 23.20, Uncertain significance, Cockayne syndrome; Xeroderma pigmentosum, group F; Fanconi anemia complementatio
- A7V (p.Ala7Val), rs1319883296, ClinGen CA394815849, ClinVar RCV003016417, TOPMed rs1319883296, REVEL 0.04, CADD 17.10, Uncertain significance, Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementatio
- A7S (p.Ala7Ser), gnomAD 16-13920184-G-T, REVEL 0.10, CADD 22.70
- A7D (p.Ala7Asp), gnomAD 16-13920185-C-A, REVEL 0.24, CADD 17.20
- A7A (p.Ala7Ala), rs759774291, gnomAD 16-13920186-T-C, CADD 8.04
- R8* (p.Arg8Ter), rs774510191, ClinGen CA394815859, NCI-TCGA Cosmic COSV1003, cosmic curated COSV10031, CADD 32.00, Pathogenic
- R8G (p.Arg8Gly), ExAC rs774510191, TOPMed rs774510191, gnomAD rs774510191, REVEL 0.05, CADD 3.39, Pathogenic
- R8L (p.Arg8Leu), NCI-TCGA Cosmic COSV1003, cosmic curated COSV10031, ExAC rs759843019, TOPMed rs759843019, REVEL 0.09, CADD 13.50, Variant assessed as somatic; moderate impact.
- R8Q (p.Arg8Gln), ExAC rs759843019, TOPMed rs759843019, gnomAD rs759843019, REVEL 0.08, CADD 13.10, Uncertain significance, Xeroderma pigmentosum, group F; Fanconi anemia complementation group Q; Cockayne
- R8R (p.Arg8Arg), rs774510191, gnomAD 16-13920187-C-A, CADD 5.26
- R9G (p.Arg9Gly), rs1326609617, ClinGen CA394815864, ClinVar RCV002650366, ClinVar RCV006357503, REVEL 0.10, CADD 7.07, Uncertain significance, Inborn genetic diseases; Xeroderma pigmentosum, group F; Fanconi anemia compleme
- R9L (p.Arg9Leu), gnomAD rs1214498950, REVEL 0.03, CADD 0.21, Uncertain significance
- R9P (p.Arg9Pro), rs1214498950, ClinGen CA394815872, ClinVar RCV001059205, gnomAD rs1214498950, REVEL 0.03, CADD 0.12, Uncertain significance, Cockayne syndrome; Xeroderma pigmentosum, group F; Fanconi anemia complementatio
- R9Q (p.Arg9Gln), gnomAD rs1214498950, REVEL 0.01, CADD 0.07, Uncertain significance
- R9W (p.Arg9Trp), cosmic curated COSV61314, TOPMed rs1326609617, gnomAD rs1326609617, REVEL 0.14, CADD 15.70
- R9R (p.Arg9Arg), rs1260753835, gnomAD 16-13920192-G-C, CADD 5.81
- I10S (p.Ile10Ser), Ensembl rs2141936944
- I10T (p.Ile10Thr), gnomAD 16-13920194-T-C, REVEL 0.04, CADD 2.98
- A11S (p.Ala11Ser), cosmic curated COSV10588, ExAC rs767738598, TOPMed rs767738598, gnomAD rs767738598, REVEL 0.05, CADD 15.90
- A11T (p.Ala11Thr), ExAC rs767738598, TOPMed rs767738598, gnomAD rs767738598, REVEL 0.03, CADD 17.80
- A11V (p.Ala11Val), rs753596005, ClinGen CA7910066, ClinVar RCV001220164, ExAC rs753596005, REVEL 0.07, CADD 20.70, Uncertain significance, Fanconi anemia complementation group Q; Xeroderma pigmentosum, group F; Cockayne
- A11D (p.Ala11Asp), gnomAD 16-13920197-C-A, REVEL 0.07, CADD 20.40
- A11A (p.Ala11Ala), rs3136042, gnomAD 16-13920198-C-T, CADD 5.52
- M12I (p.Met12Ile), TOPMed rs1366397352, REVEL 0.19, CADD 23.90, Uncertain significance, Inborn genetic diseases; Xeroderma pigmentosum, group F; Cockayne syndrome
- M12L (p.Met12Leu), ExAC rs750358005, gnomAD rs750358005, REVEL 0.20, CADD 24.00, Uncertain significance
- M12T (p.Met12Thr), NCI-TCGA Cosmic COSV6131, cosmic curated COSV61314, Variant assessed as somatic; moderate impact.
- M12V (p.Met12Val), rs750358005, ClinGen CA7910069, ClinVar RCV003062927, ClinVar RCV005019613, REVEL 0.19, CADD 23.50, Uncertain significance, XFE progeroid syndrome; Xeroderma pigmentosum, group F; Fanconi anemia complemen
- M12W (p.Met12Trp), gnomAD 16-13920196-GC-G, CADD 22.80
- M12R (p.Met12Arg), gnomAD 16-13920200-T-G, REVEL 0.35, CADD 28.40
- M12K (p.Met12Lys), gnomAD 16-13920200-T-A, REVEL 0.36, CADD 27.20
- A13E (p.Ala13Glu), ExAC rs751008601, TOPMed rs751008601, gnomAD rs751008601, REVEL 0.27, CADD 25.80
- A13S (p.Ala13Ser), rs374243778, ClinGen CA7910070, ClinVar RCV001056526, ClinVar RCV005055151, REVEL 0.28, CADD 22.90, Uncertain significance, Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementatio
- A13T (p.Ala13Thr), rs374243778, ClinGen CA7910071, ClinVar RCV002508160, ClinVar RCV002541036, REVEL 0.20, CADD 23.60, Uncertain significance, not provided; Behavioral variant of frontotemporal dementia; Fanconi anemia comp
- A13V (p.Ala13Val), ExAC rs751008601, TOPMed rs751008601, gnomAD rs751008601, REVEL 0.21, CADD 24.20
- A13A (p.Ala13Ala), rs112419956, gnomAD 16-13920204-G-A, CADD 14.70
- P14A (p.Pro14Ala), TOPMed rs2031939647, gnomAD rs2031939647, REVEL 0.06, CADD 21.80
- P14L (p.Pro14Leu), rs754622238, ClinGen CA7910073, ClinVar RCV000462139, ExAC rs754622238, REVEL 0.17, CADD 25.00, Uncertain significance, Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementatio
- P14R (p.Pro14Arg), rs754622238, ClinGen CA10647746, ClinVar RCV000281667, ExAC rs754622238, REVEL 0.18, CADD 28.00, Uncertain significance, Xeroderma pigmentosum, group F
- P14T (p.Pro14Thr), gnomAD 16-13920205-C-A, REVEL 0.16, CADD 22.40
- P14S (p.Pro14Ser), gnomAD 16-13920205-C-T, REVEL 0.12, CADD 22.50
- P14Q (p.Pro14Gln), gnomAD 16-13920206-C-A, REVEL 0.19, CADD 27.70
- P14P (p.Pro14Pro), rs2141936987, gnomAD 16-13920207-G-A, CADD 12.50
- L15Q (p.Leu15Gln), gnomAD rs1455284562
- L15R (p.Leu15Arg), gnomAD rs1455284562, REVEL 0.51, CADD 31.00
- L15L (p.Leu15Leu), rs140734311, gnomAD 16-13920208-C-T, CADD 13.40
- L15V (p.Leu15Val), gnomAD 16-13920208-C-G, REVEL 0.23, CADD 24.40
- L16M (p.Leu16Met), Ensembl rs2141937002
- L16P (p.Leu16Pro), gnomAD rs1301287370, REVEL 0.78, CADD 32.00
- L16L (p.Leu16Leu), rs1364867115, gnomAD 16-13920213-G-A, CADD 14.90
- E17* (p.Glu17Ter), cosmic curated COSV61313, ESP rs368281878, TOPMed rs368281878, gnomAD rs368281878, CADD 44.00
- E17A (p.Glu17Ala), Ensembl rs1596616470
- E17G (p.Glu17Gly), Ensembl rs1596616470, REVEL 0.43, CADD 31.00
- E17Q (p.Glu17Gln), ESP rs368281878, TOPMed rs368281878, gnomAD rs368281878, REVEL 0.18, CADD 29.90
- E17V (p.Glu17Val), Ensembl rs1596616470
- E17D (p.Glu17Asp), gnomAD 16-13920216-G-T, REVEL 0.09, CADD 20.40
- Y18F (p.Tyr18Phe), gnomAD rs1284921995, REVEL 0.08, CADD 22.90
- Y18C (p.Tyr18Cys), gnomAD 16-13920218-A-G, REVEL 0.30, CADD 25.40
- Y18Y (p.Tyr18Tyr), rs2141937022, gnomAD 16-13920219-C-T, CADD 7.63
- E19* (p.Glu19Ter), TOPMed rs1210853201, CADD 45.00
- E19G (p.Glu19Gly), Ensembl rs2141937029
- E19K (p.Glu19Lys), rs1210853201, ClinGen CA394815993, ClinVar RCV003990100, Uncertain significance, XFE progeroid syndrome
- E19D (p.Glu19Asp), gnomAD 16-13920222-G-C, REVEL 0.23, CADD 22.90
- E19E (p.Glu19Glu), gnomAD 16-13920222-G-A, CADD 12.90
- R20* (p.Arg20Ter), rs1355878901, ClinGen CA394816007, ClinVar RCV002037756, TOPMed rs1355878901, CADD 39.00, Pathogenic
- R20R (p.Arg20Arg), gnomAD 16-13920225-A-G, CADD 15.60
- Q21E (p.Gln21Glu), rs748499820, ClinGen CA7910075, cosmic curated COSV61311, ClinVar RCV000334401, REVEL 0.07, CADD 22.60, Uncertain significance, Fanconi anemia complementation group Q; Xeroderma pigmentosum, group F; Cockayne
- Q21H (p.Gln21His), ESP rs375896908, ExAC rs375896908, TOPMed rs375896908, gnomAD rs375896908, REVEL 0.22, CADD 27.90
- Q21L (p.Gln21Leu), ExAC rs756494000, TOPMed rs756494000, gnomAD rs756494000, REVEL 0.32, CADD 28.30
- Q21P (p.Gln21Pro), ExAC rs756494000, TOPMed rs756494000, gnomAD rs756494000, REVEL 0.39, CADD 28.00
- Q21R (p.Gln21Arg), ExAC rs756494000, TOPMed rs756494000, gnomAD rs756494000, REVEL 0.21, CADD 26.70
- Q21K (p.Gln21Lys), gnomAD 16-13920226-C-A, REVEL 0.13, CADD 24.40
- Q21* (p.Gln21Ter), gnomAD 16-13920226-C-T, CADD 41.00
- Q21Q (p.Gln21Gln), gnomAD 16-13920228-G-A, CADD 13.70
- L22P (p.Leu22Pro), TOPMed rs1318270871, gnomAD rs1318270871, REVEL 0.38, CADD 25.30
- L22Q (p.Leu22Gln), TOPMed rs1318270871, gnomAD rs1318270871
- L22V (p.Leu22Val), Ensembl rs2031940688, REVEL 0.04, CADD 19.50
- L22L (p.Leu22Leu), gnomAD 16-13920229-C-T, CADD 13.50
- L22M (p.Leu22Met), gnomAD 16-13920229-C-A, REVEL 0.04, CADD 16.00
- V23A (p.Val23Ala), 1000Genomes rs1291749487, gnomAD rs1291749487
- V23G (p.Val23Gly), 1000Genomes rs1291749487, gnomAD rs1291749487, REVEL 0.21, CADD 25.10
- V23M (p.Val23Met), TOPMed rs1296707814, gnomAD rs1296707814, REVEL 0.17, CADD 25.20
- V23L (p.Val23Leu), gnomAD 16-13920232-G-C, REVEL 0.09, CADD 23.10
- V23V (p.Val23Val), gnomAD 16-13920234-G-C, CADD 13.00
- L24M (p.Leu24Met), gnomAD rs1225226851, REVEL 0.39, CADD 24.40
- L24Q (p.Leu24Gln), TOPMed rs900748752
- L24L (p.Leu24Leu), rs1225226851, gnomAD 16-13920235-C-T, CADD 13.40
- L24P (p.Leu24Pro), gnomAD 16-13920236-T-C, REVEL 0.57, CADD 32.00
- E25* (p.Glu25Ter), 1000Genomes rs560047653, ExAC rs560047653, gnomAD rs560047653, CADD 42.00
- E25Q (p.Glu25Gln), rs560047653, ClinGen CA394816053, ClinVar RCV003800214, REVEL 0.11, CADD 27.40, Uncertain significance, Xeroderma pigmentosum, group F; Fanconi anemia complementation group Q; Cockayne
- E25V (p.Glu25Val), ExAC rs745893266, TOPMed rs745893266, gnomAD rs745893266, REVEL 0.20, CADD 32.00
- E25G (p.Glu25Gly), gnomAD 16-13920239-A-G, REVEL 0.13, CADD 26.50
- L26M (p.Leu26Met), gnomAD rs1177929089, REVEL 0.12, CADD 24.10
- L26V (p.Leu26Val), gnomAD rs1177929089, REVEL 0.08, CADD 22.70
- L26L (p.Leu26Leu), rs1177929089, gnomAD 16-13920241-C-T, CADD 14.70
- L27F (p.Leu27Phe), rs587778282, ClinGen CA158858, ClinVar RCV000120804, ClinVar RCV000372597, REVEL 0.05, CADD 21.20, Uncertain significance, Xeroderma pigmentosum, group F; Fanconi anemia complementation group Q; Cockayne
- L27H (p.Leu27His), Ensembl rs1040349747, REVEL 0.15, CADD 23.90
- L27R (p.Leu27Arg), gnomAD 16-13920245-T-G, REVEL 0.30, CADD 31.00
- L27P (p.Leu27Pro), gnomAD 16-13920245-T-C, REVEL 0.44, CADD 32.00
- L27L (p.Leu27Leu), rs1389032539, gnomAD 16-13920246-C-G, CADD 6.53
- D28E (p.Asp28Glu), Ensembl rs2031941694, REVEL 0.12, CADD 15.60
- D28G (p.Asp28Gly), rs367608263, ClinGen CA7910083, ClinVar RCV003788050, ClinVar RCV005836570, REVEL 0.05, CADD 23.00, Uncertain significance, Cockayne syndrome; Fanconi anemia complementation group Q; Xeroderma pigmentosum
- D28H (p.Asp28His), cosmic curated COSV10460, TOPMed rs1188439403, REVEL 0.03, CADD 20.40
- D28N (p.Asp28Asn), TOPMed rs1188439403, REVEL 0.06, CADD 20.70
- D28V (p.Asp28Val), ESP rs367608263, ExAC rs367608263, TOPMed rs367608263, gnomAD rs367608263, Uncertain significance
- D28Y (p.Asp28Tyr), gnomAD 16-13920247-G-T, REVEL 0.04, CADD 23.00
- D28D (p.Asp28Asp), rs2031941694, gnomAD 16-13920249-C-T, CADD 12.60
- T29A (p.Thr29Ala), ExAC rs765069053, gnomAD rs765069053, REVEL 0.05, CADD 14.00
- T29I (p.Thr29Ile), rs1370047760, ClinGen CA394816101, ClinVar RCV001820238, gnomAD rs1370047760, REVEL 0.06, CADD 21.70, Uncertain significance, not specified
- T29S (p.Thr29Ser), gnomAD 16-13920251-C-G, REVEL 0.08, CADD 15.10
- T29T (p.Thr29Thr), gnomAD 16-13920252-T-C, CADD 10.10
- D30A (p.Asp30Ala), rs878853037, ClinGen CA10581313, ClinVar RCV000224195, Ensembl rs878853037, AlphaMissense 0.61, MetaLR 0.35, Uncertain significance, not provided
- D30E (p.Asp30Glu), rs1304744260, TOPMed rs1304744260, gnomAD rs1304744260, ClinGen CA394816117, REVEL 0.46, CADD 26.10, Uncertain significance, Xeroderma pigmentosum, group F; Fanconi anemia complementation group Q; Cockayne
- D30G (p.Asp30Gly), NCI-TCGA TCGA novel, Ensembl rs878853037, REVEL 0.61, AlphaMissense 0.61, Uncertain significance
- D30Y (p.Asp30Tyr), gnomAD 16-13920253-G-T, REVEL 0.65, CADD 32.00
- D30D (p.Asp30Asp), rs1304744260, gnomAD 16-13920255-C-T, CADD 15.00
- G31R (p.Gly31Arg), rs996650792, TOPMed rs996650792, gnomAD rs996650792, ClinGen CA394816119, REVEL 0.66, CADD 33.00, Uncertain significance, Inborn genetic diseases
- G31W (p.Gly31Trp), gnomAD 16-13920256-G-T, REVEL 0.62, CADD 33.00
- G31V (p.Gly31Val), gnomAD 16-13920257-G-T, REVEL 0.57, CADD 30.00
- G31G (p.Gly31Gly), gnomAD 16-13920258-G-T, CADD 13.50
- L32I (p.Leu32Ile), gnomAD rs1451460766, REVEL 0.52, CADD 25.80
- L32V (p.Leu32Val), gnomAD rs1451460766, REVEL 0.51, CADD 26.50
- L32* (p.Leu32Ter), gnomAD 16-13920255-CG-C, CADD 32.00
- L32L (p.Leu32Leu), gnomAD 16-13920259-C-T, CADD 19.10
- V33A (p.Val33Ala), rs1287910269, ClinGen CA394816145, cosmic curated COSV10885, ClinVar RCV002258703, REVEL 0.19, CADD 25.20, Uncertain significance, Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementatio
- V33L (p.Val33Leu), rs34205098, UniProt VAR 057477, Ensembl rs34205098, REVEL 0.04, CADD 22.40
- V33I (p.Val33Ile), gnomAD 16-13920262-G-A, REVEL 0.10, CADD 23.00
- V33V (p.Val33Val), rs952244517, gnomAD 16-13920264-A-G, CADD 4.67
- V34L (p.Val34Leu), Ensembl rs61731714
- V34M (p.Val34Met), rs61731714, ClinGen CA394816150, ClinVar RCV003154735, ClinVar RCV003778920, REVEL 0.46, CADD 28.50, Conflicting interpretations, Cockayne syndrome; Fanconi anemia complementation group Q; Xeroderma pigmentosum
- V34V (p.Val34Val), rs2031942483, gnomAD 16-13920267-G-A, CADD 14.10
- C35* (p.Cys35Ter), ExAC rs762885804, TOPMed rs762885804, gnomAD rs762885804, CADD 36.00, Likely benign
- C35F (p.Cys35Phe), gnomAD rs2031942578, REVEL 0.13, CADD 24.80
- C35Y (p.Cys35Tyr), gnomAD rs2031942578, REVEL 0.21, CADD 27.60
- C35W (p.Cys35Trp), gnomAD 16-13920270-C-G, REVEL 0.36, CADD 24.90
- C35C (p.Cys35Cys), rs762885804, gnomAD 16-13920270-C-T, CADD 13.70
- A36D (p.Ala36Asp), Ensembl rs2141937199
- A36P (p.Ala36Pro), rs2141937194, ClinGen CA394816172, ClinVar RCV002608594, AlphaMissense 0.82, MetaLR 0.53, Uncertain significance, Xeroderma pigmentosum, group F; Cockayne syndrome; Fanconi anemia complementatio
- A36T (p.Ala36Thr), Ensembl rs2141937194, REVEL 0.55, AlphaMissense 0.82
- A36S (p.Ala36Ser), gnomAD 16-13920271-G-T, REVEL 0.32, CADD 25.50
- A36A (p.Ala36Ala), gnomAD 16-13920273-C-A, CADD 13.80
- R37C (p.Arg37Cys), rs144602005, ClinGen CA7910087, ClinVar RCV001066566, ClinVar RCV003238298, REVEL 0.21, CADD 29.90, Uncertain significance, not provided; Xeroderma pigmentosum, group F; Cockayne syndrome
- R37H (p.Arg37His), cosmic curated COSV61311, Ensembl rs2141937217, REVEL 0.23, CADD 30.00
- R37S (p.Arg37Ser), 1000Genomes rs144602005, ESP rs144602005, ExAC rs144602005, TOPMed rs144602005, REVEL 0.13, CADD 24.10, Uncertain significance
- R37L (p.Arg37Leu), gnomAD 16-13920275-G-T, REVEL 0.23, CADD 25.90
- R37R (p.Arg37Arg), rs1014770923, gnomAD 16-13920276-C-T, CADD 14.50
Public ERCC4 analysis runs
- ERCC4 analysis run — ERCC4 (1,851 variants) — completed 2026-08-19